Biocryst Pharmaceuticals (BCRX) Free Cash Flow Growth (5y) (2015 - 2026)
Biocryst Pharmaceuticals (BCRX) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.96 Bn | 32.22 Bn | 1.97 Bn |
| 3 | Zoetis | 32.55 Bn | 30.61 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.05 Bn | 20.90 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.36 Bn | 2.29 Bn | 151.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.42% |
| Dec 31, 2025 | 54.71% |
| Sep 30, 2025 | 25.13% |
| Jun 30, 2025 | 26.92% |
| Mar 31, 2025 | -3.30% |
| Dec 31, 2024 | 14.67% |
| Sep 30, 2024 | 17.93% |
| Jun 30, 2024 | 45.96% |
| Mar 31, 2024 | -14.76% |
| Dec 31, 2023 | 21.23% |
| Sep 30, 2023 | 9.85% |
| Jun 30, 2023 | -6.49% |
| Mar 31, 2023 | -19.35% |
| Dec 31, 2022 | -18.05% |
| Sep 30, 2022 | -20.92% |
| Jun 30, 2022 | -23.65% |
| Mar 31, 2022 | -55.76% |
| Dec 31, 2021 | -41.81% |
| Sep 30, 2021 | -5.91% |
| Jun 30, 2021 | -15.03% |